Literature DB >> 10433616

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

K A Gelmon1, E A Eisenhauer, A L Harris, M J Ratain, P Workman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10433616     DOI： 10.1093/jnci/91.15.1281

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  27 in total

1.  Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.

Authors:  Kenichiro Enooku; Ryosuke Tateishi; Fumihiko Kanai; Yuji Kondo; Ryota Masuzaki; Tadashi Goto; Shuichiro Shiina; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2011-09-21       Impact factor: 7.527

2.  Balancing safety, effectiveness, and public desire: the FDA and cancer.

Authors:  Rena Conti
Journal:  Issue Brief (Commonw Fund)       Date:  2003-04

3.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

4.  Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.

Authors:  Nicolas Penel; Alain Duhamel; Antoine Adenis; Patrick Devos; Nicolas Isambert; Stéphanie Clisant; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2010-11-04       Impact factor: 3.850

Review 5.  Translational research in phase I trials.

Authors:  Angelica Fasolo; Cristiana Sessa
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 6.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

7.  In vivo detection of phospholipase C by enzyme-activated near-infrared probes.

Authors:  Theresa M Mawn; Anatoliy V Popov; Nancy J Beardsley; Klara Stefflova; Matthew Milkevitch; Gang Zheng; E James Delikatny
Journal:  Bioconjug Chem       Date:  2011-11-29       Impact factor: 4.774

8.  A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.

Authors:  Simon Pacey; Martin Gore; David Chao; Udai Banerji; James Larkin; Sarah Sarker; Karen Owen; Yasmin Asad; Florence Raynaud; Mike Walton; Ian Judson; Paul Workman; Tim Eisen
Journal:  Invest New Drugs       Date:  2010-08-05       Impact factor: 3.850

9.  Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.

Authors:  Elisabeth I Heath; Patricia M LoRusso; S Percy Ivy; Larry Rubinstein; Michaele C Christian; Lance K Heilbrun
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

10.  Increasing complexity in oncology phase I clinical trials.

Authors:  Laeeq Malik; David Lu
Journal:  Invest New Drugs       Date:  2018-11-16       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.